Collaboration provides Laurus access to Willow's AI-driven bioengineering platform The strategic alliance includes an initial seven high-value advanced intermediates and active pharmaceutical ingredients, including Willow's corticosteroid programs The agreement with Laurus is the largest collaboration agreement Willow has signed to date SUNNYVALE, Calif., May 30, 2024 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces a multi-product development and licensing partnership with Laurus Labs ("Laurus") (Bombay Stock Exchange Code: 540222; LAURUSLABS-IN: National Stock Exchange of India), a leading research-driven pharmaceutical and biotechnology company with a ...

TORONTO, May 29, 2024 /CNW/ - Baylin Technologies Inc. (TSX: BYL) (the "Company") is pleased to announce that its Advantech Wireless Technologies Inc. ("Advantech") subsidiary has received an $8.2M order for its ultra-high-power Summit II Solid State Power Amplifier (SSPA) systems. This order was placed by a major US defence contractor for use in a NATO government specific application.

SASKATOON, SK, May 27, 2024 /CNW/ - Star Diamond Corporation ("Star Diamond") is pleased to provide a review of the work completed by Rio Tinto Exploration Canada Inc. ("RTEC") on the Fort à la Corne Project ("FalC Project"). From June 2017 until June 2022, RTEC pursued extensive exploration and evaluation analysis on two fronts at the FalC Project...

Real world evidence demonstrates pharmaceutical support programs positively impact patient persistence with clozapine treatmentStudy highlights significant differences in clozapine persistence rates across pharmaceutical support programsDORVAL, QC, May 28, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that results from a Quebec-based retrospective study examining the positive impact of pharmaceutical support programs ("PSPs") on persistence with clozapine treatment have been published in the Journal of Clinical Pharmacology and Therapeutics.